ASN-LABS
Has ASN-LABS received an FDA warning letter? Yes. FDA issued a warning letter dated September 9, 2025 concerning products containing retatrutide and semaglutide and tirzepatide.
Letter facts
- Letter date
- September 9, 2025 (2025-09-09)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Telehealth
- Products named
- compounded retatrutidecompounded semaglutidetirzepatide
- Violation categories
- Unapproved new drugMisbrandingCompounding outside 503A/503BFalse or misleading claims
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
Compounding outside 503A/503B
FDA says this pharmacy's compounded products did not meet the conditions that let pharmacies compound drugs without FDA approval. A warning letter is FDA's notice of what it believes are significant violations; the company can respond.
False or misleading claims
FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.
Factual Violation Summary
FDA says compounded retatrutide is an unapproved new drug lacking adequate directions for use and not eligible for 503A/503B exemptions; semaglutide claims implying equivalence to FDA-approved Wegovy and Ozempic are false or misleading, misbranding the products.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- unapproved new drugs
- misbranded drugs
- false or misleading claims
- failure to meet 503A/503B conditions
More letters about Retatrutide
Recent FDA warning letters concerning Retatrutide:
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
- Peptide Partners LLCAugust 24, 2026
- Peak Performance PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.